Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
20 hedge funds and large institutions have $4.63M invested in Landos Biopharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.
10.73% more ownership
Funds ownership: 39.11% → 49.84% (+11%)
13% less funds holding
Funds holding: 23 → 20 (-3)
41% less capital invested
Capital invested by funds: $7.87M → $4.63M (-$3.24M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.8K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$27.1K |
| 3 |
BlackRock
New York
|
+$3.48K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.18K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
-$31.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.2K |
| 3 |
HF
HRT Financial
New York
|
-$26K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$22.1K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$20.9K |
LABP Hedge Fund Activity: Q1 2023 in Review
20 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q1 2023, worth a combined $4.63M — down 41% from $7.87M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LABP and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.8K. The largest seller was Steel Grove Capital Advisors, cutting an estimated $31.2K.
- 20 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q1 2023, down from 23 in Q4 2022.
- Funds reported $4.63M of Landos Biopharma, Inc. Common Stock stock for Q1 2023, down 41% quarter-over-quarter.
- 3 funds opened new Landos Biopharma, Inc. Common Stock positions in Q1 2023 and 6 closed out, a net change of -3 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q1 2023 was Citadel Advisors, an estimated $31.8K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q1 2023 was Steel Grove Capital Advisors, an estimated $31.2K sold.
Based on aggregated 13F filings for Q1 2023.